Compass Therapeutics Posts Wider Q2 Loss

Compass Therapeutics (NASDAQ:CMPX), a clinical-stage biotechnology company focused on developing novel bispecific antibody therapies for cancer, released its second quarter results on August 11, 2025. The company reported a net loss per share of $(0.14) (GAAP) in the second quarter, missing analyst expectations of $(0.12) GAAP EPS. Revenue (GAAP) was in line with expectations at $0, following the loss of one-time revenue from the prior-year period. Cash reserves (GAAP) declined from $127 million as of December 31, 2024, to $101 million as of June 30, 2025, but are still projected to last into 2027. Overall, the quarter saw sustained progress in clinical development alongside higher expenses as programs advanced.

Source: Analyst estimates for the quarter provided by FactSet.

Compass Therapeutics is advancing new treatments for cancer using bispecific antibodies. The company’s pipeline features drug candidates at various stages, including tovecimig for biliary tract cancer and two other antibodies, CTX-8371 and CTX-10726, in early clinical development.

Continue reading

Source Fool.com